Atul Bedi

Associate Professor

19932018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 4 Similar Profiles
Apoptosis Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences
Phosphotransferases Medicine & Life Sciences
Tumors Chemical Compounds
Cell Death Medicine & Life Sciences
DNA Damage Medicine & Life Sciences
Death Domain Receptors Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1993 2018

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

Ravi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., Artemov, A. V., Wysocki, P. T., Mehra, R., Nimmagadda, S., Marchionni, L., Sidransky, D., Borrello, I. M., Izumchenko, E. & Bedi, A. Dec 1 2018 In : Nature Communications. 9, 1, 741

Research output: Contribution to journalArticle

beta factor
CTLA-4 Antigen
antibodies
Transforming Growth Factor beta
Immunotherapy

Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors

Izumchenko, E. , Paz, K. , Ciznadija, D. , Sloma, I. , Katz, A. , Vasquez-Dunddel, D. , Ben-Zvi, I. , Stebbing, J. , McGuire, W. , Harris, W. , Maki, R. , Gaya, A. , Bedi, A. , Zacharoulis, S. , Ravi, R. , Wexler, L. H. , Hoque, M. O. , Rodriguez-Galindo, C. , Pass, H. , Peled, N. & 4 others Davies, A., Morris, R., Hidalgo, M. & Sidransky, D. 2017 In : Annals of Oncology. 28, 10, p. 2595-2605 11 p.

Research output: Contribution to journalArticle

Heterografts
Neoplasms
Therapeutics
Exome
Translational Medical Research

SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in head and neck cancer cells

Ozawa, H., Ranaweera, R. S., Izumchenko, E., Makarev, E., Zhavoronkov, A., Fertig, E. J., Howard, J. D., Markovic, A., Bedi, A., Ravi, R., Perez, J., Le, Q. T., Kong, C. S., Jordan, R. C., Wang, H., Kang, H., Quon, H., Sidransky, D. & Chung, C. H. Sep 1 2017 In : Clinical Cancer Research. 23, 17, p. 5162-5175 14 p.

Research output: Contribution to journalArticle

Head and Neck Neoplasms
Gene Knockdown Techniques
Phenotype
Cell Line
Cetuximab

Patient-derived xenografts as tools in pharmaceutical development

Izumchenko, E., Meir, J., Bedi, A., Wysocki, P. T., Hoque, M. O. & Sidransky, D. 2016 (Accepted/In press) In : Clinical Pharmacology and Therapeutics.

Research output: Contribution to journalArticle

Heterografts
Pharmaceutical Preparations
Neoplasms
Decision Making
Therapeutics

A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma

Gilbert, J., Schell, M. J., Zhao, X., Murphy, B., Tanvetyanon, T., Leon, M. E., Hayes, D. N., Haigentz, M., Saba, N., Nieva, J., Bishop, J., Sidransky, D., Ravi, R., Bedi, A. & Chung, C. H. 2015 In : Oral Oncology. 51, 4, p. 376-382 7 p.

Research output: Contribution to journalArticle

Disease-Free Survival
Neoplasms
Cytokines
Human papillomavirus 6
sorafenib